Eager to speed the pace of clinical innovation, many patient groups fund or operate drug discovery and development programs. These groups’ in-depth understanding of the unmet medical needs of patients and carers, their up-to-the-moment knowledge of the research and development landscape, their connections to thought leaders, and in many cases their candidate portfolios can enhance companies’ business development and licensing efforts.
MK&A has pioneered the definition and development of PLRNs. To learn more about PLRNs and how MK&A can help you attain your business goals through partnerships with PLRNs, download our white paper below.
To help a company maximize the benefit of engaging with patient-led research networks, MK&A also offers:
Tailored workshops to identify optimal outcomes and pathways
Using our signature digital assessment platform, LEAD, we assess and prioritize networks best aligned with business needs, including a list of assets of interest to the company
Innovative ways to meet and assess PLRN assets: e.g., a “pitch and partner day” where priority groups are invited to learn more about the company and present their best assets
Detailed opportunities for extended engagement to further assess value of assets and in- or out-license as appropriate
Collaborative discussions to help advance therapeutic targets
Training on patient reported outcomes, evaluating company goals in and planning for patient centricity, building strong and compliant advocacy relations. Standard operating procedures for BD&L’s interaction with PLRNs